- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04416282
Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure.
Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure- A Randomized Open Label Study.
Study Overview
Status
Intervention / Treatment
Detailed Description
Aim To compare the effect of Early initiation of Terlipressin (ET arm) to albumin at 12 hour in ACLF patients with non-volume responsive AKI versus standard Terlipressin (ST arm) at 48 hours.
Primary Objective Efficacy of early terlipressin infusion in comparison to Standard treatment for resolution of AKI at day 7.
Secondary Objectives
- Full and partial AKI response at 48 and 72 h and 96 hours
- Mortality at Day 28, Day 90
- Baseline organ failure(s), MELD, CLIF-SOFA score and ACLF score
- New onset organ failures
- Urine Output
- Progression or resolution of OFs at day 7
- Change in MELD, CLIF-SOFA score and ACLF score at day 7
- Change in NGAL, FENa, FE-Urea at day 7
- Treatment related adverse effects and their grades
Methodology:
Study population:
All patients admitted to the Institute of Liver and Biliary Sciences (ILBS) with ACLF with AKI- HRS will be evaluated for inclusion. ACLF will be defined by the APASL criteria.
Study Design A prospective, randomized, single center open label study
Study Period:Two year
Intervention & monitoring:
Clinical Protocol An informed consent will be taken from ACLF patients with AKI within 24-hours of admission. No alteration in the treatment or investigative procedures of the included patients will be done. All included patients will be followed from admission till death or discharge. All discharged patients will then be followed till 30-days.
Preliminary work up
At admission:
(A) Complete history and physical examination
- Recent Diuretics use
- Loose stools
- Recurrent vomiting
- Fever, signs of sepsis (SIRS)
- H/s/o LRTI, SSTI, SBP
- Recent contrast use (< 7 days)
- Use of nephrotoxins including NSAIDs
- Prior renal dysfunction, known CKD, HD
- History of HTN, Diabetes
- History of renal stones
- History s/o hypotensive episodes (shock)
Pre-randomization interventions:
(B) Intervention during 0-12 hours (Before randomization) -
- Withdrawal of diuretics
- Withdrawal of lactulose (in patients with loose stools)
- Urine output monitoring (catheterize and monitor hourly or 12 h cumulative)
- 2 hourly MAP, Pulse rate
- Empirical IV antibiotics to be given in case of suspected/proven sepsis (Avoid nephrotoxic drugs e.g Amikacin, Colistin, Amphotericin etc as possible)
- IV hydration with albumin at 12 hours preferably 40 g (20 %) + 500 ml crystalloids)
Labs and follow-up:
- Baseline (at admission) - Blood : KFT, LFT, CBC, INR, Blood c/s, pro-BNP Imaging : USG abdomen, USG KUB, Renal doppler, C-X-ray, 2D ECHO Urine : Urine R/E and cultures, Urine Na, Urea, NGAL, Creatinine, FENa, FE Urea A/F analysis - for SBP
- At 12 hours (Before randomization) - Blood - KFT
- At D1, D2, D3, D5, D7, D14, D28 post randomization Blood : KFT Urine : Urine Na, Urea, NGAL, Creatinine, FENa, FE Urea (At Day 3 and 7) Imaging : Renal doppler (Day 3)
Clinical evaluation:
- Etiology of cirrhosis (Baseline)
- Severity of liver disease (Baseline, D3, D7) MELD score, CLIF-SOFA score, MELD-Na score, AARC score
- Stage of ACLF (Baseline,D3, D7) AARC grade, CLIF ACLF grade
- Complications / Organ failures (Baseline,D3, D7) HE, Bleed, AKI stage, SBP, Infection (specify site and severity) Respiratory and circulatory failure
Follow up duration Duration of admission till discharge or death will be noted. Patients will be followed up to 28-days for re-admission(s) and survival.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Dr Hitesh Singh, MD
- Phone Number: 01146300000
- Email: hiteshrims04@gmail.com
Study Locations
-
-
Delhi
-
New Delhi, Delhi, India, 110070
- Institute of Liver & Biliary Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-65 years
- ACLF as per APASL criteria
- AKI at admission as defined by ICA-AKI criteria
- AKI stage 2/3 at 12 hour of admission
Exclusion Criteria:
-
At Admission:
- Age <18 years
- Patients on renal replacement therapy (RRT)
- Post renal or liver transplantation
- History of CAD, ischemic cardiomyopathy, PVD, ventricular arrhythmia
- Decompensated cirrhosis not fulfilling ACLF criteria
- Cirrhotics with AKI managed as outpatients
- Grade III/IV HE or Shock requiring inotropes or patients on mechanical ventilator at time of randomization
- In-hospital new AKI
- Active urinary sediments - 2+ albumin or above, dysmorphic RBCs
- Known CKD, obstructive uropathy
- Lack of informed consent
- Prior intolerance or S/E to Terlipressin or albumin
At 12 Hour before randomization:
• Regression of AKI (>0.3 mg/dl) above baseline after IV albumin (20% 40 gm) + IV Crystalloids 500 ml therapy for 12 hours
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Terlipressin + Albumin
Injection terlipressin 2 mg/24 hours infusion + i/v albumin 1g/Kg/day
|
Injection terlipressin 2 mg/24 hours infusion
i/v albumin 1g/Kg/day
|
Active Comparator: Albumin
i/v albumin 1g/Kg/day for next 36 hours f/b inj terlipressin 2mg/24 hours
|
i/v albumin 1g/Kg/day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Acute Kidney Injury reversal by day 7 in both groups
Time Frame: Day 7
|
Day 7
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mortality in both groups
Time Frame: Day 28
|
Day 28
|
Mortality in both groups
Time Frame: Day 90
|
Day 90
|
Progression or resolution of Organ failures
Time Frame: Day 90
|
Day 90
|
Adverse Events in both groups
Time Frame: Day 90
|
Day 90
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Kidney Diseases
- Urologic Diseases
- Liver Diseases
- Liver Failure, Acute
- Renal Insufficiency
- End Stage Liver Disease
- Liver Failure
- Hepatic Insufficiency
- Acute-On-Chronic Liver Failure
- Acute Kidney Injury
- Hepatorenal Syndrome
- Antihypertensive Agents
- Vasoconstrictor Agents
- Terlipressin
Other Study ID Numbers
- ILBS-ACLF-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute-On-Chronic Liver Failure
-
Chulalongkorn UniversityRecruitingAcute-On-Chronic Liver Failure | Acute on Chronic Hepatic FailureThailand
-
Third Affiliated Hospital, Sun Yat-Sen UniversityWithdrawnLiver Failure, Acute on ChronicChina
-
Tianjin Weikai Bioeng., Ltd.Tianjin Nankai HospitalUnknownLiver Failure, Acute on ChronicChina
-
Aga Khan UniversityNational Institute of Liver & GI Diseases, PakistanNot yet recruiting
-
Nanfang Hospital of Southern Medical UniversityCompletedLiver Injury | Liver Failure, Acute on Chronic
-
Pere GinesClinica Universidad de Navarra, Universidad de NavarraTerminatedAllogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure (Liveradvance)Acute on Chronic Hepatic FailureSpain
-
Nanfang Hospital of Southern Medical UniversityCompletedThrombelastography,Acute on Chronic Liver Failure, PlateletChina
-
Hexaell Biotech Co., Ltd.RecruitingLiver Failure | Hepatitis | Acute on Chronic Hepatic FailureChina
-
Hepa Wash GmbHTerminatedAcute on Chronic Hepatic FailureGermany
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute on Chronic Hepatic FailureIndia
Clinical Trials on Terlipressin
-
First Affiliated Hospital, Sun Yat-Sen UniversityCompleted
-
MallinckrodtCompletedHepatorenal SyndromeUnited States
-
Ferring PharmaceuticalsCompletedGastrointestinal Bleeding | Oesophageal VaricesRomania
-
Pere GinesUnknownCirrhosis | Hepatorenal Syndrome Type ISpain
-
Assaf-Harofeh Medical CenterUnknown
-
BioVie Inc.CompletedCirrhosis | Ascites HepaticUnited States
-
Aga Khan UniversityMallinckrodtUnknown
-
Aga Khan UniversityFerozsons Laboratories Ltd.CompletedHemorrhage | Portal Hypertension | Esophageal VaricesPakistan
-
Hospital Clinic of BarcelonaGrant from Education Ministery from 2001-2004.SuspendedCirrhosis | Hepatorenal SyndromeSpain
-
University of PadovaUnknownCirrhosis | Type 1 Hepatorenal SyndromeItaly